Quantcast

Latest Glycoproteins Stories

2014-03-28 08:26:41

MONROVIA, Calif., March 28, 2014 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today presented an overview of its bispecific antibody programs at the Annual Summit on Practical and Emerging Trends in Multiple Myeloma being held in Whistler, British Columbia, Canada. The discussion featured Xencor's bispecific approach...

2014-03-24 08:29:41

SAN FRANCISCO, March 24, 2014 /PRNewswire/ -- Sutro Biopharma, a biopharmaceutical company developing a new generation of protein therapeutics, including next-generation antibody drug conjugates and bispecific antibodies, today announced that it will present at the 21(st) Annual Future Leaders in the Biotech Industry Conference taking place on March 28, 2014, at the Millennium Broadway Hotel & Conference Center in New York City. William J. Newell, chief executive officer of...

2014-03-19 16:23:41

Conference call to be held today at 4:30 p.m. EDT MONROVIA, Calif., March 19, 2014 /PRNewswire/ -- Xencor Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today reported financial results for the fourth quarter and full year ended December 31, 2013 and provided a review of business highlights. "We are very pleased that Xencor now has five clinical...

2014-03-19 08:30:18

PARSIPPANY, N.J., March 19, 2014 /PRNewswire-USNewswire/ -- Ferring Pharmaceuticals Inc. today announced FDA approval of new labeling for their fertility products, MENOPUR and BRAVELLE. The label update is a result of the COMBINE trial which demonstrated that both MENOPUR and BRAVELLE can be safely mixed and administered in a single injection. Approval was granted on February 19, 2014 and designates Ferring's mixed protocol as the only combination of IVF stimulation gonadotropins to...

2014-03-13 08:28:19

SAN DIEGO, March 13, 2014 /PRNewswire/ -- AnaptysBio, Inc., a leader in the discovery and development of therapeutic antibodies, today announced a strategic immuno-oncology collaboration with TESARO, Inc. (NASDAQ: TSRO), an oncology-focused biopharmaceutical company. Under the terms of the agreement, AnaptysBio has granted TESARO exclusive rights to antibody programs targeting PD-1, TIM-3 and LAG-3, including monospecific and dual reactive antibody drug candidates. Antibody...

2014-03-11 16:25:50

AUSTIN, Texas, March 11, 2014 /PRNewswire/ -- XBiotech announced today that the United States Patent and Trademark Office (USPTO) granted another key patent to support the Company's growing portfolio around its lead product candidate. The new patent grants XBiotech exclusive rights to target a unique molecule associated with chronic sterile inflammation. The patent relates to antibodies and methods of using these antibodies to treat, prevent, and detect disease progression associated...

2014-03-10 23:24:13

Xtalks presents an exciting live webinar on Wednesday, March 26, 2014 at 11:00 EDT (15:00 GMT). Join keynote speaker Dr. Dhaval Shah, Assistant Professor at the Department of Pharmaceutical Sciences, University at Buffalo, for a one-hour presentation to learn Using PK/PD modeling for Antibody Drug Conjugate Translation. Toronto, Canada (PRWEB) March 10, 2014 Antibody Drug Conjugates (ADCs) are at the forefront of the therapeutic market. The first therapeutic antibody was approved by the...

2014-03-07 08:21:14

DUBLIN, Mar. 07, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/cl5vpz/antibody_target ) has announced the addition of the "Concise Database for Antibody Target, Technology & Pipeline: 1-Year Subscription" subscription to their offering. (Logo:http://photos.prnewswire.com/prnh/20130307/600769) Subscription to La Merie Publishing's proprietary Antibody Database provides online access to information about more than 2,400 project entries for...

2014-03-05 08:29:20

DUBLIN, March 5, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/r8hfhg/fc_protein_and) has announced the addition of the "Fc Protein and Glycoengineered Antibodies Market" [http://www.researchandmarkets.com/research/r8hfhg/fc_protein_and ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Engineered antibodies are antibody based therapeutics, which are gaining increasing attention from...

2014-03-05 04:22:20

DUBLIN, March 5, 2014 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/885sfr/bispecific ) has announced the addition of the "Concise Analysis of the International Bispecific Antibody Therapeutics Market" [http://www.researchandmarkets.com/research/885sfr/bispecific ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Antibody based therapeutics are the fastest growing segment of the drugs and...


Word of the Day
baudekin
  • A rich embroidered or brocaded silk fabric woven originally with a warp of gold thread.
'Baudekin' seems to be an alternative form of 'baldachin,' from the Italian 'Baldacco,' Baghdad, the city where the material was made.
Related